Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2003 1
2008 1
2011 1
2013 1
2014 1
2015 2
2016 3
2020 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
An automated synthesis of 177Lu-EDTMP as an efficient bone-seeking therapeutic radiopharmaceutical.
Elboga U, Kilbas B, Sahin E, Cayırlı YB, Eryilmaz K, Begec T, Bakar HE, Mercanoglu G, Celen YZ. Elboga U, et al. Eur Rev Med Pharmacol Sci. 2021 Jul;25(14):4829-4834. doi: 10.26355/eurrev_202107_26396. Eur Rev Med Pharmacol Sci. 2021. PMID: 34337731 Free article.
The therapeutic efficacy of 177Lu-EDTMP at 1-, 3-, 6-, and 8-weeks post-therapy was evaluated using Standard Pain Scoring Assessment Criteria. ...During the study, 75 patients (57 M: 18 F, mean age: 68.0 11.1 years) of breast/prostate cancer with documented skeletal …
The therapeutic efficacy of 177Lu-EDTMP at 1-, 3-, 6-, and 8-weeks post-therapy was evaluated using Standard Pain Scoring Asse …
Synthesis and Ready to Use Kit Formulation of EDTMP for the Preparation of 177Lu-EDTMP as a Bone Palliation Radiopharmaceutical.
Mercanoglu G, Zilbeyaz K, Arslan N. Mercanoglu G, et al. Curr Radiopharm. 2023;16(1):38-43. doi: 10.2174/1874471015666220721095938. Curr Radiopharm. 2023. PMID: 35899954 Free PMC article.
Ethylenediamine-tetramethylene phosphonic acid (EDTMP) is a preferred carrier molecule for radiolanthanides, such as (177)Lu. The present paper describes the synthesis of EDTMP and the development of a ready-to-use kit for the preparation of (177)Lu-EDTMP and its quality c …
Ethylenediamine-tetramethylene phosphonic acid (EDTMP) is a preferred carrier molecule for radiolanthanides, such as (177)Lu. The present pa …
Clinical Efficacy and Safety Comparison of 177Lu-EDTMP with 153Sm-EDTMP on an Equidose Basis in Patients with Painful Skeletal Metastases.
Thapa P, Nikam D, Das T, Sonawane G, Agarwal JP, Basu S. Thapa P, et al. J Nucl Med. 2015 Oct;56(10):1513-9. doi: 10.2967/jnumed.115.155762. Epub 2015 Aug 27. J Nucl Med. 2015. PMID: 26315829 Free article. Clinical Trial.
Pain relief was categorized as complete, partial, minimal, or none. RESULTS: Pain relief with 177Lu-EDTMP was 80%: 50% complete, 41.67% partial, and 8.33% minimal. ...Quality of life at 3 mo after therapy improved significantly in both groups as per ECOG score (P=0. …
Pain relief was categorized as complete, partial, minimal, or none. RESULTS: Pain relief with 177Lu-EDTMP was 80%: 50% complet …
Pharmacokinetic, Dosimetry and Toxicity Study of 177Lu-EDTMP in Patients: Phase 0/I study.
Bal C, Arora G, Kumar P, Damle N, Das T, Chakraborty S, Banerjee S, Venkatesh M, Zaknun JJ, Pillai MR. Bal C, et al. Curr Radiopharm. 2016;9(1):71-84. doi: 10.2174/1874471008666150313105000. Curr Radiopharm. 2016. PMID: 25771371 Clinical Trial.
Herein, we report the pharmacokinetics, dosimetry and toxicity analysis of 177Lu-EDTMP in patients (phase-0/I study). In a phase-0 study, the biokinetics of skeletal and non-skeletal uptake of 177Lu-EDTMP was assessed in 6 patients with metastatic pros …
Herein, we report the pharmacokinetics, dosimetry and toxicity analysis of 177Lu-EDTMP in patients (phase-0/I study). In a pha …
Cellular toxicity and apoptosis studies in osteocarcinoma cells, a comparison of 177Lu-EDTMP and Lu-EDTMP.
Kumar C, Korde A, Kumari KV, Das T, Samuel G. Kumar C, et al. Curr Radiopharm. 2013 Sep;6(3):146-51. doi: 10.2174/18744710113069990021. Curr Radiopharm. 2013. PMID: 23895775
OBJECTIVE: The most promising bone pain palliative agent such as 177Lu-EDTMP emerges as a newer radiopharmaceutical for cancer management. ...Cellular toxicity studies were carried out with varying amounts of 177Lu-EDTMP and compared with equivalent am …
OBJECTIVE: The most promising bone pain palliative agent such as 177Lu-EDTMP emerges as a newer radiopharmaceutical for cancer …
Evaluation of 177Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy.
Chakraborty S, Balogh L, Das T, Polyák A, Andócs G, Máthé D, Király R, Thuróczy J, Chaudhari PR, Jánoki GA, Jánoki G, Banerjee S, Pillai MR. Chakraborty S, et al. Curr Radiopharm. 2016;9(1):64-70. doi: 10.2174/1874471008666150312164255. Curr Radiopharm. 2016. PMID: 25771374
177Lu-EDTMP is currently being investigated as a potential agent for providing palliative care to the patients suffering from bone pain due to metastatic skeletal carcinoma. ...The dogs were treated with a dose of ~44.4 MBq (1.2 mCi) per kg body weight of 177Lu …
177Lu-EDTMP is currently being investigated as a potential agent for providing palliative care to the patients suffering from …
Theranostic Applications of Lutetium-177 in Radionuclide Therapy.
Das T, Banerjee S. Das T, et al. Curr Radiopharm. 2016;9(1):94-101. doi: 10.2174/1874471008666150313114644. Curr Radiopharm. 2016. PMID: 25771364
In the present article, the possibility of using two 177Lu-based agents viz. 177Lu-EDTMP and 177Lu-DOTATATE for theranostic applications in metastatic bone pain palliation (MBPP) and peptide receptor radionuclide therapy (PRRT), have been explored. In the case of …
In the present article, the possibility of using two 177Lu-based agents viz. 177Lu-EDTMP and 177Lu-DOTATATE for theranostic ap …
14 results